Idera Pharmaceuticals Inc - Revizia istoricului

127.0.0.1: The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).

2024-11-26T10:19:55Z

The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).

← Versiunea anterioară		Versiunea de la data 26 noiembrie 2024 13:19
Linia 2:		Linia 2:

	==Descriere companie==		==Descriere companie==
	Idera Pharmaceuticals, Inc. (http://www.iderapharma.com/) is a clinical-stage biopharmaceutical company focused on clinical development and commercialization of drug candidates for both oncology and rare disease. The Company is engaged on Toll-like receptor (TLR) agonist, tilsotolimod (IMO-2125), for oncology. It uses its chemistry-based platform to design both TLR agonists and antagonists to act by modulating the activity of targeted TLRs. Its TLR-targeted clinical-stage drug candidate, tilsotolimod, is an agonist of TLR9. The Company is developing tilsotolimod, via intratumoral injection in combination with inhibitors and costimulation therapies for the treatment of various solid tumors, including anti-programmed-death-receptor-1 (anti-PD1) refractory metastatic melanoma, microsatellite stable (MSS) colorectal cancer (CRC) and squamous cell carcinoma of the [[head]] and neck (HNSCC). It refers tilsotolimod development program as the ILLUMINATE development program.		Idera Pharmaceuticals, Inc. (http://www.iderapharma.com/) is a clinical-stage biopharmaceutical company focused on clinical development and commercialization of drug candidates for both oncology and rare disease. The Company is engaged on Toll-like receptor (TLR) agonist, tilsotolimod (IMO-2125), for oncology. It uses its chemistry-based platform to design both TLR agonists and antagonists to act by modulating the activity of targeted TLRs. Its TLR-targeted clinical-stage drug candidate, tilsotolimod, is an agonist of TLR9. The Company is developing tilsotolimod, via intratumoral injection in combination with inhibitors and costimulation therapies for the treatment of various solid tumors, including anti-programmed-death-receptor-1 (anti-PD1) refractory metastatic melanoma, microsatellite stable (MSS) colorectal cancer ([[CRC]]) and squamous cell carcinoma of the [[head]] and neck (HNSCC). It refers tilsotolimod development program as the ILLUMINATE development program.

	==Grafic actiuni companie==		==Grafic actiuni companie==

127.0.0.1: The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).

2024-10-01T10:07:25Z

The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).

← Versiunea anterioară		Versiunea de la data 1 octombrie 2024 13:07
Linia 2:		Linia 2:

	==Descriere companie==		==Descriere companie==
	Idera Pharmaceuticals, Inc. (http://www.iderapharma.com/) is a clinical-stage biopharmaceutical company focused on clinical development and commercialization of drug candidates for both oncology and rare disease. The Company is engaged on Toll-like receptor (TLR) agonist, tilsotolimod (IMO-2125), for oncology. It uses its chemistry-based platform to design both TLR agonists and antagonists to act by modulating the activity of targeted TLRs. Its TLR-targeted clinical-stage drug candidate, tilsotolimod, is an agonist of TLR9. The Company is developing tilsotolimod, via intratumoral injection in combination with inhibitors and costimulation therapies for the treatment of various solid tumors, including anti-programmed-death-receptor-1 (anti-PD1) refractory metastatic melanoma, microsatellite stable (MSS) colorectal cancer (CRC) and squamous cell carcinoma of the head and neck (HNSCC). It refers tilsotolimod development program as the ILLUMINATE development program.		Idera Pharmaceuticals, Inc. (http://www.iderapharma.com/) is a clinical-stage biopharmaceutical company focused on clinical development and commercialization of drug candidates for both oncology and rare disease. The Company is engaged on Toll-like receptor (TLR) agonist, tilsotolimod (IMO-2125), for oncology. It uses its chemistry-based platform to design both TLR agonists and antagonists to act by modulating the activity of targeted TLRs. Its TLR-targeted clinical-stage drug candidate, tilsotolimod, is an agonist of TLR9. The Company is developing tilsotolimod, via intratumoral injection in combination with inhibitors and costimulation therapies for the treatment of various solid tumors, including anti-programmed-death-receptor-1 (anti-PD1) refractory metastatic melanoma, microsatellite stable (MSS) colorectal cancer (CRC) and squamous cell carcinoma of the [[head]] and neck (HNSCC). It refers tilsotolimod development program as the ILLUMINATE development program.

	==Grafic actiuni companie==		==Grafic actiuni companie==

Admin: Pagină nouă: Pagina dedicata companiei Idera Pharmaceuticals Inc listata cu simbolul US.IDRA ==Descriere companie== Idera Pharmaceuticals, Inc. (http://www.iderapharma.com/) is a clinical-stage biopharmaceutical company focused on clinical development and commercialization of drug candidates for both oncology and rare disease. The Company is engaged on Toll-like receptor (TLR) agonist, tilsotolimod (IMO-2125), for oncology. It uses its chemistry-based platform to design both TLR agonists...

2024-09-18T18:03:57Z

Pagină nouă: Pagina dedicata companiei Idera Pharmaceuticals Inc listata cu simbolul US.IDRA ==Descriere companie== Idera Pharmaceuticals, Inc. (http://www.iderapharma.com/) is a clinical-stage biopharmaceutical company focused on clinical development and commercialization of drug candidates for both oncology and rare disease. The Company is engaged on Toll-like receptor (TLR) agonist, tilsotolimod (IMO-2125), for oncology. It uses its chemistry-based platform to design both TLR agonists...

Pagină nouă

Pagina dedicata companiei Idera Pharmaceuticals Inc listata cu simbolul US.IDRA

==Descriere companie==
Idera Pharmaceuticals, Inc. (http://www.iderapharma.com/) is a clinical-stage biopharmaceutical company focused on clinical development and commercialization of drug candidates for both oncology and rare disease. The Company is engaged on Toll-like receptor (TLR) agonist, tilsotolimod (IMO-2125), for oncology. It uses its chemistry-based platform to design both TLR agonists and antagonists to act by modulating the activity of targeted TLRs. Its TLR-targeted clinical-stage drug candidate, tilsotolimod, is an agonist of TLR9. The Company is developing tilsotolimod, via intratumoral injection in combination with inhibitors and costimulation therapies for the treatment of various solid tumors, including anti-programmed-death-receptor-1 (anti-PD1) refractory metastatic melanoma, microsatellite stable (MSS) colorectal cancer (CRC) and squamous cell carcinoma of the head and neck (HNSCC). It refers tilsotolimod development program as the ILLUMINATE development program.

==Grafic actiuni companie==
<iframe key="tradeville" path="graficSimbol/US.IDRA" />

==Ultimele stiri despre Idera Pharmaceuticals Inc (US.IDRA)==
<dynamicpagelist>
category=US.IDRA
count=10
order=descending
addfirstcategorydate=false
</dynamicpagelist>

[[Categorie:US.IDRA]][[Categorie:Stiri despre companii]]